Dan Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dan Zhou has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Li Yang
Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
3 shared publications - LeYu Zhou
Department of Gastroenterology and Hepatology and Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital Sichuan University Chengdu Sichuan Province China
2 shared publications Yi Shen
Department of Gastroenterology and Hepatology, and Laboratory of Gastrointestinal Cancer and Liver Disease West China Hospital, Sichuan University Chengdu Sichuan Province China
2 shared publications- Yongqi Dong
Department of Gastroenterology and Hepatology, and Laboratory of Gastrointestinal Cancer and Liver Disease West China Hospital, Sichuan University Chengdu Sichuan Province China
2 shared publications Kunyi Ba
Department of Gastroenterology and Hepatology, and Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital, Sichuan University, Chengdu, China, scu.edu.cn
1 shared publication- Tingting Jia
Department of Gastroenterology and Hepatology, and Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital, Sichuan University, Chengdu, China, scu.edu.cn
1 shared publication
Latest Publications
- 13 July 2026
- Published by Wiley in Liver International
- Vol. 46 (8) , e70796
Reply to ‘Biopsy Before Autoimmune Hepatitis Withdrawal: The Estimand Matters’
- 13 July 2026
- Published by Wiley in Liver International
- Vol. 46 (8) , e70796
Reply to ‘Biopsy Before Autoimmune Hepatitis Withdrawal: The Estimand Matters’
- 20 April 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70642
Relapse After Treatment Withdrawal in Autoimmune Hepatitis: Biopsy‐Guided Versus Clinically Guided Strategies—A Meta‐Analysis
Long‐term immunosuppression in autoimmune hepatitis (AIH) carries substantial side effects, making treatment withdrawal an important consideration after sustained biochemical remission. Whether biopsy‐guided withdrawal based on histological assessment reduces relapse compared with clinically guided withdrawal remains uncertain. We conducted a systematic review and meta‐analysis to compare relapse rates between these two strategies. This meta‐analysis followed PRISMA 2020. PubMed, Embase, Web of Science, Scopus and the Cochrane Library were searched from inception to identify studies reporting relapse after treatment withdrawal in AIH using biopsy‐guided or clinically guided strategies. Pooled relapse rates were estimated using random‐effects models of transformed proportions. Prespecified subgroup, sensitivity and meta‐regression analyses evaluated the impact of relapse definitions, histological stringency and follow‐up duration. Twelve studies (518 patients) were included. The pooled relapse rate after treatment withdrawal was 51.1%. Relapse rates were not significantly different between biopsy‐guided (48.3%) and clinically guided withdrawal (56.3%; p = 0.604). Studies defining relapse by transaminase elevation alone reported higher relapse rates than those incorporating IgG elevation. Within biopsy‐guided cohorts, stricter histological remission thresholds were associated with lower relapse rates and reduced heterogeneity.Relapse after treatment withdrawal in AIH remained common and did not differ significantly between biopsy‐guided and clinically guided strategies. In the context of existing guideline recommendations, current evidence does not clearly support routine prewithdrawal liver biopsy in all patients with sustained biochemical remission. Trial Registration: PROSPERO registration number: 4202511295
- 20 April 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70642
Relapse After Treatment Withdrawal in Autoimmune Hepatitis: Biopsy‐Guided Versus Clinically Guided Strategies—A Meta‐Analysis
Long‐term immunosuppression in autoimmune hepatitis (AIH) carries substantial side effects, making treatment withdrawal an important consideration after sustained biochemical remission. Whether biopsy‐guided withdrawal based on histological assessment reduces relapse compared with clinically guided withdrawal remains uncertain. We conducted a systematic review and meta‐analysis to compare relapse rates between these two strategies. This meta‐analysis followed PRISMA 2020. PubMed, Embase, Web of Science, Scopus and the Cochrane Library were searched from inception to identify studies reporting relapse after treatment withdrawal in AIH using biopsy‐guided or clinically guided strategies. Pooled relapse rates were estimated using random‐effects models of transformed proportions. Prespecified subgroup, sensitivity and meta‐regression analyses evaluated the impact of relapse definitions, histological stringency and follow‐up duration. Twelve studies (518 patients) were included. The pooled relapse rate after treatment withdrawal was 51.1%. Relapse rates were not significantly different between biopsy‐guided (48.3%) and clinically guided withdrawal (56.3%; p = 0.604). Studies defining relapse by transaminase elevation alone reported higher relapse rates than those incorporating IgG elevation. Within biopsy‐guided cohorts, stricter histological remission thresholds were associated with lower relapse rates and reduced heterogeneity.Relapse after treatment withdrawal in AIH remained common and did not differ significantly between biopsy‐guided and clinically guided strategies. In the context of existing guideline recommendations, current evidence does not clearly support routine prewithdrawal liver biopsy in all patients with sustained biochemical remission. Trial Registration: PROSPERO registration number: 4202511295
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2026 (1) , e8512168
Recompensation of Liver Cirrhosis: Definition, Mechanism, Etiological Differences, Prognosis, and Challenges
The progression from compensated to decompensated cirrhosis has historically been considered irreversible. However, accumulating clinical evidence has given rise to the concept of “recompensation,” which posits that a subset of patients with decompensated cirrhosis may regain a compensated state following successful etiological control, leading to a markedly improved prognosis. This review synthesizes current evidence on cirrhosis recompensation, examining its definition, mechanisms, and etiological specificities, while also addressing the prognosis and persistent challenges in this patient population. Further research is needed to refine the definition of recompensation and elucidate the underlying mechanisms and determinants.
- 1 January 2026
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2026 (1) , e8512168
Open AccessRecompensation of Liver Cirrhosis: Definition, Mechanism, Etiological Differences, Prognosis, and Challenges
The progression from compensated to decompensated cirrhosis has historically been considered irreversible. However, accumulating clinical evidence has given rise to the concept of “recompensation,” which posits that a subset of patients with decompensated cirrhosis may regain a compensated state following successful etiological control, leading to a markedly improved prognosis. This review synthesizes current evidence on cirrhosis recompensation, examining its definition, mechanisms, and etiological specificities, while also addressing the prognosis and persistent challenges in this patient population. Further research is needed to refine the definition of recompensation and elucidate the underlying mechanisms and determinants.